XFOR (X4 Pharmaceuticals) Total Assets: $270.28 Mil (As of Mar. 2026)


XFOR X4 Pharmaceuticals Inc XFOR
29 GF Score
Price $3.97
! 7 Warning Signs
View Full Analysis

What is X4 Pharmaceuticals Total Assets?

X4 Pharmaceuticals XFOR -2.93% 29 Total Assets is $270.28 Mil as of Mar. 2026. GuruFocus rates XFOR with a GF Score™ of 29/100. The stock has 7 warning signs investors should review.

X4 Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 was $270.28 Mil.

During the past 12 months, X4 Pharmaceuticals's average Total Assets Growth Rate was -15.10% per year. During the past 3 years, the average Total Assets Growth Rate was 3.40% per year. During the past 5 years, the average Total Assets Growth Rate was -0.50% per year. During the past 10 years, the average Total Assets Growth Rate was 33.70% per year.

During the past 11 years, X4 Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 114.70%. The lowest was -9.20%. And the median was 15.90%.

Total Assets is connected with ROA %. X4 Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 was -28.88%. Total Assets is also linked to Revenue through Asset Turnover. X4 Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 was 0.01.

X4 Pharmaceuticals  (NAS:XFOR) Total Assets Explanation

Total Assets is connected with ROA %.

X4 Pharmaceuticals's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-80.964/( (290.461+270.281)/ 2 )
=-80.964/280.371
=-28.88 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

X4 Pharmaceuticals's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=2.708/( (290.461+270.281)/ 2 )
=2.708/280.371
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

X4 Pharmaceuticals Total Assets Related Terms

X4 Pharmaceuticals Total Assets Historical Data

* Premium members only.

The historical data trend for X4 Pharmaceuticals's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

X4 Pharmaceuticals Total Assets Chart

X4 Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 117.18 155.59 147.26 146.45 290.46

X4 Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 130.01 105.17 163.56 290.46 270.28
XFOR
29GF Score
X4 Pharmaceuticals Inc XFOR
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

X4 Pharmaceuticals Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

X4 Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=186.29+104.171
=290.46

X4 Pharmaceuticals's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=168.45+101.831
=270.28

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $270.28 Mil mean?
X4 Pharmaceuticals (XFOR) has a Total Assets of $270.28 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on X4 Pharmaceuticals and its competitors.
Is X4 Pharmaceuticals' Total Assets too high?
X4 Pharmaceuticals' current Total Assets is $270.28 Mil. Overall, X4 Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does X4 Pharmaceuticals' Total Assets compare to ZURA and LYEL?
X4 Pharmaceuticals' Total Assets of $270.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on X4 Pharmaceuticals and its competitors. X4 Pharmaceuticals's current Total Assets is $270.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is X4 Pharmaceuticals stock overvalued right now?
X4 Pharmaceuticals (XFOR) has a current Total Assets of $270.28 Mil. The current Total Assets is $270.28 Mil. X4 Pharmaceuticals' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For X4 Pharmaceuticals (XFOR), the current Total Assets is $270.28 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

X4 Pharmaceuticals Business Description

Address 61 North Beacon Street, 4th Floor, Boston, MA, USA, 02134
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
29GF Score

Get the complete analysis for XFOR

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.97
Price